Item 8.01 Other Events.
On February 4, 2013, the Company issued a press release announcing its February
1, 2013 receipt of a Complete Response Letter from the FDA regarding our NDA for
Ampligen®.
A copy of the press release, dated February 4, 2013, is attached as Exhibit 99.1
to this Current Report on Form 8-K. The information in Exhibit 99.1 shall not be
deemed filed for purposes of Section 18 of the Exchange Act and shall not be
deemed incorporated by reference into filings under the Securities Act.
Add
HEB to Portfolio
Set Alert
Email to a
Friend